Physician profile
Kevin Jovanovic
NPI 1417955980
$9,703.73
in general payments reported to CMS, 2019-2025
39 companies · $586 in 2025
The $586 reported for 2025 was more than what 90% of Maternal & Fetal Medicine providers received nationally (typical 2025 total: $55.21).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,819 · 2020: $904 · 2021: $1,436 · 2022: $1,360 · 2023: $414 · 2024: $185 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,185.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kci USA, INC. | $3,820.42 | 2019-2020 | |
| Abbvie INC. | $1,135.01 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $537.86 | 2021-2025 | |
| Therapeuticsmd, INC. | $496.15 | 2019-2022 | |
| Agile Therapeutics, INC. | $319.55 | 2021-2024 | Twirla |
| Davol INC. | $283.98 | 2021 | |
| Millicent US INC | $274.14 | 2019-2025 | Intrarosa, Femlyv |
| Allergan, INC. | $264.66 | 2019-2022 | |
| Scynexis, INC. | $254.70 | 2022 | |
| Avion Pharmaceuticals | $252.76 | 2020-2022 | |
| Duchesnay USA Incorporated | $176.59 | 2019 | |
| Sumitomo Pharma America, INC. | $157.75 | 2024-2025 | Gemtesa, Myfembree |
| Vertical Pharmaceuticals, LLC | $157.30 | 2019-2020 | |
| Daiichi Sankyo INC. | $140.42 | 2022 | |
| Hologic Sales and Service, LLC | $113.08 | 2019-2025 | Novasure, Aptima |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Jovanovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.